Published in Hepatitis Weekly, October 21st, 2002
The study will compare the protective immune response of patients after immunization with either Engerix-B HBV vaccine, a commercially available hepatitis B vaccine, or recombinant hepatitis B surface antigen (rHBsAg) coadministered with Dynavax's proprietary immunostimulatory DNA sequences (1018-ISS). Infection with the hepatitis B virus (HBV) is a major global health problem, with 350...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.